APGE Apogee Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Clinical-stage biotech developing breakthrough therapeutics focused on protein modulation and drug candidates
• • Emphasis on zumilokibart (APG777) with $76.4M R&D spend in 2025, up $27.2M YoY, reflecting clinical trial expansion and manufacturing scale-up

Management Discussion & Analysis

• • No revenue or profitability figures disclosed for fiscal year 2026 due to clinical-stage status
• • Pipeline focus on four antibody programs targeting inflammatory and immunology diseases, no segment financials given

Risk Factors

• • New geopolitical risk from conflicts involving Russia, Ukraine, Israel, and Hamas impacting financial markets and capital raising ability
• • Updated financial risk: net loss $186.5M for nine months ended Sep 30, 2025; cash runway now into second half of 2028

What are the latest APGE SEC filings in 2026?

Apogee Therapeutics, Inc. (APGE) has filed a 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 10, 2025, an 8-K current report on April 24, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did APGE file its most recent 10-K annual report?

Apogee Therapeutics, Inc. (APGE) filed its most recent 10-K annual report on March 2, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view APGE 10-Q quarterly reports?

Apogee Therapeutics, Inc. (APGE)'s most recent 10-Q quarterly report was filed on November 10, 2025. SignalX displays every APGE 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has APGE filed recently?

Apogee Therapeutics, Inc. (APGE)'s most recent 8-K was filed on April 24, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find APGE insider trading activity (Form 4)?

SignalX aggregates every APGE Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does APGE file with the SEC?

Apogee Therapeutics, Inc. (APGE) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new APGE filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Apogee Therapeutics, Inc. (APGE).

What is APGE's SEC CIK number?

Apogee Therapeutics, Inc. (APGE)'s SEC CIK (Central Index Key) number is 1974640. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1974640 to look up all APGE filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find APGE return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Apogee Therapeutics, Inc. (APGE) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.